A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms EMPOwER
- Sponsors Novartis Healthcare; Novartis Pharmaceuticals
- 09 Nov 2019 Planned primary completion date changed from 15 Nov 2019 to 7 Feb 2020.
- 11 Feb 2019 Planned primary completion date changed from 7 Feb 2020 to 15 Nov 2019.
- 14 Feb 2018 Status changed from not yet recruiting to recruiting.